Comparison of proportional and differential odds models for mixed-effects analysis of categorical data

In this work a model for analyzing categorical data is presented; the differential odds model. Unlike the commonly used proportional odds model, this model does not assume that a covariate affects all categories equally on the log odds scale. The differential odds model was compared to the proportional odds model, by assessing statistical significance and improvement of predictive performance when applying the differential odds model to data previously analyzed using the proportional odds model. Three clinical studies; 3-category T-cell receptor density data, 5-category diarrhea data and 6-category sedation data, were re-analyzed with the differential odds model. As expected, no improvements were seen with T-cell receptor density and diarrhea data. However, for the more complex measurement sedation, the differential odds model provided both statistical improvements and improvements in simulation properties. The estimated actual critical value was for all data lower than the nominal value, using the number of added parameters as the degree of freedom, i.e. the differential odds model is statistically indicated to a less extent than expected. The differential odds model had the desired property of not being indicated when not necessary, but it may provide improvements when the data does not represent a categorization of continuous data.

[1]  N. Mayo,et al.  Statistical assessment of ordinal outcomes in comparative studies. , 1997, Journal of clinical epidemiology.

[2]  M. Dowsett,et al.  Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David Hinkley,et al.  Bootstrap Methods: Another Look at the Jackknife , 2008 .

[4]  D. Stram,et al.  Variance components testing in the longitudinal mixed effects model. , 1994, Biometrics.

[5]  Mats O Karlsson,et al.  Pharmacokinetics of Ximelagatran and Relationship to Clinical Response in Acute Deep Vein Thrombosis , 2005, Clinical pharmacology and therapeutics.

[6]  B. Efron Bootstrap Methods: Another Look at the Jackknife , 1979 .

[7]  J. Verweij,et al.  Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.

[8]  Mats O. Karlsson,et al.  Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  A. Agresti Categorical data analysis , 1993 .

[10]  L B Sheiner,et al.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.

[11]  D. Mould,et al.  Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors , 2002, Clinical pharmacology and therapeutics.

[12]  Laura Iavarone,et al.  Population Pharmacokinetic-Pharmacodynamic Model of Craving in an Enforced Smoking Cessation Population: Indirect Response and Probabilistic Modeling , 2001, Pharmaceutical Research.

[13]  Lynn McFadyen,et al.  A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[14]  D R Stanski,et al.  Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.

[15]  Mats O. Karlsson,et al.  Assessment of Type I Error Rates for the Statistical Sub-model in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  L B Sheiner,et al.  Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.

[17]  Erik Olofsen,et al.  Alfentanil and Placebo Analgesia: No Sex Differences Detected in Models of Experimental Pain , 2005, Anesthesiology.

[18]  J. DeJongh,et al.  Population pharmacokinetic and pharmacodynamic modeling of propofol for long‐term sedation in critically ill patients: A comparison between propofol 6% and propofol 1% , 2002, Clinical pharmacology and therapeutics.

[19]  Mats O Karlsson,et al.  Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. , 2003, British journal of clinical pharmacology.

[20]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.

[21]  B. Armstrong,et al.  Ordinal regression models for epidemiologic data. , 1989, American journal of epidemiology.

[22]  J Wakefield,et al.  Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores , 2001, Statistics in medicine.

[23]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[24]  D. Mould,et al.  A population pharmacokinetic‐pharmacodynamic and logistic regression analysis of lotrafiban in patients , 2001, Clinical pharmacology and therapeutics.